Trial Profile
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Topotecan
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Therapeutic Use
- 12 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 12 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
- 13 Jul 2021 Status changed from suspended to active, no longer recruiting.